Pembrolizumab-Based Regimens Earn Positive CHMP Opinion in Endometrial and Cervical Cancers
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued positive opinions recommending the approval of pembrolizumab (Keytruda) in combination with carboplatin and paclitaxel, followed by pembrolizumab monotherapy, …